I am a
Home I AM A Search Login

Papers of the Week


Papers: 20 Jul 2019 - 26 Jul 2019


Animal Studies, Pharmacology/Drug Development


2019 Oct


J Pharmacol Exp Ther


371


1

Indirect AMPK activators prevent incision-induced hyperalgesia and block hyperalgesic priming while positive allosteric modulators only block priming in mice.

Authors

Inyang K, Burton MD, Szabo-Pardi T, Wentworth E, McDougal TA, Ramirez ED, Pradhan G, Dussor G, Price T
J Pharmacol Exp Ther. 2019 Oct; 371(1):138-150.
PMID: 31324647.

Abstract

AMP activated protein kinase (AMPK) is a multifunctional kinase that negatively regulates mechanistic target of rapamycin (mTOR) and mitogen activated protein kinase (MAPK) signaling, two signaling pathways that are linked to pain promotion after injury, such as surgical incision. AMPK can be activated directly using positive allosteric modulators as well as indirectly through the upregulation of upstream kinases such as liver kinase B1 (LKB1) which is a mechanism of action of metformin. Metformin's anti-hyperalgesic effects have been shown to occur only in male mice, raising questions about how metformin regulates pain sensitivity. We used metformin as well as other structurally distinct AMPK activators narciclasine, ZLN-024 and MK8722 to treat incision-induced mechanical hypersensitivity and hyperalgesic priming in male and female mice. We found that metformin was the only AMPK activator to have sex specific effects. We also found that indirect AMPK activators metformin and NCLS were able to reduce mechanical hypersensitivity and block hyperalgesic priming while direct AMPK activators, ZLN-024 and MK8722 only blocked priming. Direct and indirect AMPK activators stimulated AMPK in dorsal root ganglion (DRG) neuron cultures to a similar degree. However, incision decreased phosphorylated AMPK (p-AMPK) in DRG. Because AMPK phosphorylation is required for kinase activity, we interpret our findings as evidence that indirect AMPK activators are more effective for treating pain hypersensitivity after incision because they are able to drive increased p-AMPK through upstream kinases like LKB1. These findings have important implications for the development of AMPK-targeting therapeutics for pain treatment. SIGNIFICANCE STATEMENT: Non-opioid treatments for post-surgical pain are needed. Our work focused on whether direct or indirect AMPK activators would show greater efficacy for inhibiting incisional pain and also tested for potential sex differences. We conclude that indirect AMPK activators are likely to be more effective as potential therapeutics for post-surgical pain because they inhibit acute pain caused by incision and also prevent long-term neuronal plasticity that is involved in persistent post-surgical pain. Our work points to the natural product, indirect AMPK activator, narciclasine, as an excellent starting point for development of therapeutics.